Jacob Schwartzman

1.3k total citations
15 papers, 551 citations indexed

About

Jacob Schwartzman is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Jacob Schwartzman has authored 15 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 2 papers in Hematology. Recurrent topics in Jacob Schwartzman's work include Prostate Cancer Treatment and Research (8 papers), Protein Degradation and Inhibitors (5 papers) and Genomics, phytochemicals, and oxidative stress (4 papers). Jacob Schwartzman is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Protein Degradation and Inhibitors (5 papers) and Genomics, phytochemicals, and oxidative stress (4 papers). Jacob Schwartzman collaborates with scholars based in United States, Canada and India. Jacob Schwartzman's co-authors include Joshi J. Alumkal, Angela Gibbs, Lina Gao, Tomasz M. Beer, Motomi Mori, Rachel Slottke, Julie N. Graff, Dennis R. Koop, Myrna Y. Munar and Ganesh Cherala and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jacob Schwartzman

15 papers receiving 543 citations

Peers

Jacob Schwartzman

PRM

ONCOL

Angela Gibbs United States

Shankar Jagadeesh United States

Yu‐Hsuan Lan Taiwan

Bernard Nutley United Kingdom

Weizhi Ge China

Seok-Il Hong South Korea

Serina King United States

Wenhai Huang China

Xiaodan Sun China

Angela Gibbs United States

Jacob Schwartzman

341 ×0.8

92 ×0.6

PRM

65 ×0.7

43 ×0.8

34 ×0.7

ONCOL

Citations per year, relative to Jacob Schwartzman Jacob Schwartzman (= 1×) peers Angela Gibbs

Countries citing papers authored by Jacob Schwartzman

Since Specialization

Citations

This map shows the geographic impact of Jacob Schwartzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob Schwartzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob Schwartzman more than expected).

Fields of papers citing papers by Jacob Schwartzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob Schwartzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob Schwartzman. The network helps show where Jacob Schwartzman may publish in the future.

Co-authorship network of co-authors of Jacob Schwartzman

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob Schwartzman. A scholar is included among the top collaborators of Jacob Schwartzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob Schwartzman. Jacob Schwartzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Coleman, Daniel J., David A. Sampson, Archana Sehrawat, et al.. (2020). Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia. 22(6). 253–262. 24 indexed citations

Coleman, Daniel J., Lina Gao, Jacob Schwartzman, et al.. (2019). BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. 38(28). 5658–5669. 21 indexed citations

Coleman, Daniel J., Lina Gao, Jacob Schwartzman, et al.. (2019). Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Scientific Reports. 9(1). 3823–3823. 31 indexed citations

Schwartzman, Jacob, Daniel J. Coleman, Nicholas J. Wang, et al.. (2017). Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget. 8(67). 111084–111095. 8 indexed citations

Gao, Lina, Daniel J. Coleman, Jacob Schwartzman, et al.. (2016). Abstract 4700: BET bromodomain inhibition is a promising treatment strategy for distinct subsets of lethal castration-resistant prostate cancer. Cancer Research. 76(14_Supplement). 4700–4700. 1 indexed citations

Coleman, Daniel J., Jacob Schwartzman, Joshua A. Urrutia, et al.. (2016). Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget. 7(26). 40690–40703. 13 indexed citations

Coleman, Daniel J., Jacob Schwartzman, Nicholas Wang, et al.. (2015). Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer. Cancer Research. 75(15_Supplement). 731–731. 1 indexed citations

Alumkal, Joshi J., Rachel Slottke, Jacob Schwartzman, et al.. (2014). A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational New Drugs. 33(2). 480–489. 167 indexed citations

Gao, Lina, Jacob Schwartzman, Angela Gibbs, et al.. (2013). Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. PLoS ONE. 8(5). e63563–e63563. 99 indexed citations

10.

Weinmann, Sheila, Stephen K. Van Den Eeden, Reina Haque, et al.. (2013). Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. The Prostate. 73(13). 1371–1377. 7 indexed citations

11.

Alumkal, Joshi J., Rachel Slottke, Motomi Mori, et al.. (2013). Sulforaphane treatment in men with recurrent prostate cancer.. Journal of Clinical Oncology. 31(15_suppl). 5017–5017. 4 indexed citations

12.

Schwartzman, Jacob, Solange Mongoue‐Tchokote, Angela Gibbs, et al.. (2011). A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 6(10). 1248–1256. 15 indexed citations

13.

Schwartzman, Jacob, et al.. (2011). Synthetic cyclohexenyl chalcone natural products possess cytotoxic activities against prostate cancer cells and inhibit cysteine cathepsins in vitro. Biochemical and Biophysical Research Communications. 416(3-4). 397–402. 25 indexed citations

14.

Gibbs, Angela, et al.. (2009). Abstract #4: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating HDAC6. Cancer Research. 69. 4–4. 2 indexed citations

15.

Gibbs, Angela, et al.. (2009). Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proceedings of the National Academy of Sciences. 106(39). 16663–16668. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact